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Recommended by Alessandro Gronchi
Westudied123patientswithmalignantperipheralnervesheathtumours(MPNSTs)between1979and2002.However,90occurred
sporadically whereas 33 were associated with neuroﬁbromatosis type 1 (NF1). Survival was calculated using Kaplan-Meier survival
curves and we used Cox’s proportional hazards model to identify independent prognostic factors. A 5-year survival for 110
nonmetastatic patients was 54%; (33% NF1 and 63% sporadic P = .015). Tumour stage and site were signiﬁcant prognostic
indicators after univariate analysis. After multivariate analysis, however, only NF1 (P = .007) and tumour volume more than
200m (P = .015) remained independent predictors of poor outcome. We recommend that NF1 be taken into account during
MPNST staging. As the survival rate in the NF group was dependant on tumour volume, routine screening of these patients with
FDG PET and/or MRI may be warranted, thereby staging and controlling them at the earliest possible opportunity.
Copyright © 2009 D. E. Porter et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Malignant peripheral nerve sheath tumours (MPNSTs) are
aggressive, locally invasive soft tissue sarcomas, typically
presenting as a rapidly growing and painful lump. These
t u m o u r sa c c o u n tf o ru pt o1 0 %o fa l ls o f tt i s s u es a r c o m a s[ 1]
and are associated with poor prognosis unless wide excision
of the tumour is undertaken before local invasion or distant
metastasis can occur. The incidence of sporadic MPNSTs
is low, with a lifetime risk of 0.001% [2, 3] but in asso-
ciation with the familial condition neuroﬁbromatosis type
1 (NF1), where these tumours often arise from malignant
transformation of a plexiform neuroﬁbroma, the incidence
is much higher. Evans et al. [4] estimate the lifetime risk of
developing MPNSTs in the population of patients with NF1
to be as high as 13%. A number of studies have compared
survival in sporadic and NF1-associated tumours [1, 4–9]
but no consensus has been reached on whether NF1 is an
independent poor prognostic factor or not.
Our study aimed to determine factors important to
outcomeinalargepopulationofpatientswithMPNSTsfrom
two United Kingdom centres for soft tissue tumour surgery.
2. Patients andMethods
The medical records from 135 patients diagnosed with
MPNSTs treated between 1979 and 2002 at two UK centers
were reviewed. In 12 patients, there was insuﬃcient follow-
up data and they were excluded; leaving 123 patients that
had follow-up data from 6 months to 21 years and they were
included in the analysis.
Patients with NF1 were identiﬁed by the presence of
certaincharacteristicfeaturesbasedonthediagnosticcriteria
for NF1 [10] including features such as caf´ e au lait spots,
Lisch nodules, multiple neuroﬁbromata, and a positive
family history. A statement in the patient’s medical records
of an NF1 diagnosis was accepted as suﬃcient evidence for
that individual to be placed in the NF1 group.2 Sarcoma
Histopathologists sitting on the national musculoskeletal
tumour panel conﬁrmed the diagnoses of MPNSTs and used
the Trojani system to histologicaly grade the tumours. The
date of diagnosis taken to be the date of ﬁrst biopsy or
excision from which a histological diagnosis of MPNSTs was
made.
Operation notes and histology reports were utilised to
determine the extent of surgery and the margins achieved.
For the purposes of this analysis, amputation or wide
excision was deemed to give adequate clearance; marginal
excision and debulking were deemed to give inadequate
clearance margins. Chemotherapy and radiotherapy intents
were documented and tumour size and volume were
calculated using surgical or magnetic resonance imaging
records.
Survival data was calculated using Kaplan-Meier curves
and multivariate analysis was performed using Cox’s propor-
tional hazards model using the statistical package SPSS 13.0.
The eﬀect of each variable was compared to the eﬀect of the
group as a whole.
3. Results
Of the 123 patients in this study with MPNSTs, 33 patients
(27%) had NF1. NF1 patients were signiﬁcantly younger at
diagnosis than those with sporadic tumours with a median
ageof26yearscomparedwith53yearsforsporadicMPNSTs,
(X2 = 23.65, P<. 001). There were also signiﬁcant
diﬀerences in the distribution of the site of tumours between
the two groups with relative overrepresentation of peripheral
limb tumours in the sporadic group and axial tumours in the
NF1 group (X2 = 24.3, P<. 001) (see Figure 1). There were
no signiﬁcant diﬀerences in the tumour volumes found in
the NF1 and sporadic groups (P = .36).
Overall 5-year survival for all 123 patients was 51% and
was signiﬁcantly worse for patients with NF1 than those
with sporadic MPNSTs (32% versus 60%; P = .01). 13
patients (11%) had IUCC-TNM stage IV disease (metastases
at diagnosis). Stage IV disease was more common in NF1
patients (15%) than those with sporadic tumours (9%) but
NF1 was still associated with a signiﬁcantly worse 5-year
survival if patients with stage IV disease were removed from
the analysis (33% versus 63%; P = .015) (see Figure 2).
The eﬀect of other factors on survival in the group
of patients without metastases at diagnosis was investi-
gated using Kaplan-Meier analysis and is documented in
Table 1.
Two factors remained signiﬁcant on multivariate Cox
regression analysis. Tumours with volume <200ml had a
signiﬁcantly better prognosis (HR 0.355, 95% CI 0.15–0.82,
P = .015) than larger tumours, and NF1 tumours were
associated with signiﬁcantly poorer prognosis compared
with those occurring sporadically (HR 1.811, 95% CI 1.175–
2.791, P = .007).
Local treatment included surgery in 94% and radiother-
apy in 61%. Chemotherapy was given in 26%. 2/33 (94%)
of the NF1 group and 5/90 (94%) of the non-NF1 group
received surgery. 20/33 (65%) of the NF1 group and 55/90
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Figure 1: Tumour frequency by site.
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Figure 2: Kaplan-Meier survival in patients without metastases at
diagnosis.
(61%) of non-NF1 group received radiotherapy. The type
of treatment had no signiﬁcant eﬀect on survival. Adequate
excision margins were achieved in a similar proportion
of NF1 and sporadic tumours (31% versus 28%). Local
recurrence occurred in 24 patients. Where surgery was
attempted, adequate surgical margins were achieved in 28%
of patients, 6% of whom developed local recurrence. In
the remaining 72% of patients in whom adequate surgical
margins were not achieved, the local recurrence rate was
30%. This diﬀerence in local recurrence was statistically
signiﬁcant using the chi-square test (P<. 001).
Although patients with local recurrence displayed a
trend towards worse survival, this did not reach statistical
signiﬁcance. A trend was observed towards worse local
recurrence-free survival in NF1 (5-year survival 70% versus
81% in sporadic tumours) but this did not reach statistical
signiﬁcance.Sarcoma 3
Table 1: Univariate analysis to determine factors signiﬁcant for survival in patients without metastases at diagnosis.
Factor NF1 Sporadic All patients
5 year survival (%) P 5 year survival (%) P 5 year survival (%) P
Stage 1 100 100 100
2 46.2 .375 76.1 .079 71.1 .033
Site
Lower limb 55.6 69.4 66.7
Upper limb 100 83.3 90.9
Brachial plexus 42.9 75.0 68.4
Sciatic plexus 50.0 .139 100 .035 88.9 .036
Volume <200ml 57.1 85.7 82.9
>200ml 50.0 .119 66.7 .015 63.6 .002
Grade Low 44.4 74.2 70.0
High 50.0 .862 79.2 .713 73.4 .606
Depth Subcutaneous 50.0 90.0 83.3
Deep 50.0 .372 76.1 .755 72.2 .571
4. Discussion
Due to the relative rarity of MPNSTs, there have been few
largestudiesintosurvivalandthosereporting5-yearsurvival
lack consistency, with survival rates in the range of 39–85%
[6, 11]. Our overall survival of 51% is within this range.
There is a similar lack of consensus on the issue of whether
or not NF1 is an independent indicator of poor prognosis. A
number of studies report no signiﬁcant diﬀerence between
the 2 groups [1, 6, 11, 12]. Others, including this study
report a poorer outcome in patients with NF1 [13–18]. It
has been suggested that patients with NF1 are more likely
t op r e s e n tl a t ew i t hM P N S T sb e c a u s et h e ym a yn o tb ea s
concerned by the appearance of new swellings as the rest
of the population. In our study, a greater percentage of
NF1 patients had metastatic disease at presentation (15%
versus 9%) but even with the exclusion of these cases
from the analysis, our study of the remaining 110 patients
demonstrated 5-year survival rates in NF1 patients only half
as good as in patients with sporadic tumours. NF1 was also
an independent predictor of poor prognosis on multivariate
analysis. Possible explanations for the poorer prognosis seen
in NF1 patients include diﬀerences in the genetic proﬁle of
tumoursarisinginthese2groups[19–21]whichmightaﬀect
aggressivepotential.Othercancerssuchasbreastandovarian
cancers have also shown worse prognosis in familial cases
compared to those occurring sporadically [20, 22].
ReportsthatpatientswithNF1haveanestimatedlifetime
risk of developing MPNSTs in excess of 10% [4], in
conjunctionwithourﬁndingsofsigniﬁcantlypoorersurvival
in NF1, underline the risk posed by these tumours, and
the danger of complacency about new episodes of pain or
swellings in these individuals.
This report clearly demonstrates that patients with NF1
are diagnosed with malignancy at a signiﬁcantly younger
age than in those with sporadic tumours and is consistent
with other studies [3, 5, 9]. This reﬂects the nature of
NF1 as a familial neoplastic trait that predisposes to both
benign and malignant tumours. The NF1 gene was identiﬁed
in 1987 [23] and functions as a tumour suppressor gene.
Other familial neoplastic traits also exhibit age-dependent
malignant change at a younger age than in the general
population [20, 21].
On univariate analysis, the tumour volume, stage, and
site were also found to be signiﬁcant predictors of survival.
Tumour volume was the only other factor that, together
with NF1, remained signiﬁcant on multivariate analysis.
Histological grade was not found to correlate with survival;
however, the result may have been skewed due to small
numbers (15/129) of low-grade tumours. Recent published
data from Hagel et al. [21] support our ﬁndings that the
NF1 group is younger, has more axially located tumours, and
has a worse prognosis. Interestingly, they presented evidence
that the histopathology of NF1-associated tumours diﬀers
from the sporadic type. This may explain why we did not see
a correlation between histological grade and survival. They
postulated that and if a new grading system included NF1
as an independent prognosticator, then perhaps grade and
survival would correlate.
There was no observable diﬀerence between tumour
volumes in the sporadic and NF1 groups (P = .36).
Independent of biology, a small volume tumour oﬀers a
better prognosis because of the higher chance of achieving
wide resection margins.
We found that tumours aﬀecting the peripheral portion
of the upper limb were associated with the best survival
on univariate analysis. Interestingly, tumours sited in the
lumbosacral plexus also seemed to have a favourable prog-
nosis. Since this group represents only 11% of the total,
however, this ﬁnding should be interpreted with caution.
Peripheral lower limb tumours accounted for the greatest
proportion of tumours from the NF1 group (32%) and
formed the majority (58%) of large volume tumours. These
poor prognostic cofactors in our group of lower limb
tumours cause the univariate site-speciﬁc survival diﬀer-
ences to disappear on multivariate analysis. Other studies
have reported that peripheral rather than centrally located
t u m o u r sh a v eb e t t e rs u r v i v a lr a t e s[ 11, 15]. This is likely to4 Sarcoma
result from these tumours being more amenable to resection
with wide margins or may be because they are detected
earlier.
Recently, specialist centers have been using positron
emission tomography to detect 18F-ﬂuorodeoxyglucose
(FDG PET) uptake in these tumours. Fisher et al. [24]
showedthatFDGPETisausefultoolinmonitoringclinically
stable NF1 patients with plexiform neuroﬁbromas as it could
predict which were more likely to subsequently grow rapidly.
Also Brenner et al. [25] found that in NF1patients with
MPNSTs, higher uptakes during FDG PET were associated
with signiﬁcantly worse survival whilst histopathological
tumour grading did not predict outcome.
Deﬁnitive treatment for MPNSTs involves surgical
removal of the tumour. Adjuvant or neoadjuvant therapy
is increasingly considered but has not been shown to
consistently improve survival [11, 26]. Only ﬁve patients in
this study did not receive some form of surgical treatment.
It is well documented that these tumours can extend
considerabledistancesalongnervesandifsuspected,afrozen
sectionshouldbecarriedoutattheproximalanddistallimits
of nerve resection to ensure clear margins. Adequate surgical
margins were achieved in 31 out of 118 patients (26%) and
only 6% of these patients developed local recurrence of their
tumour, in contrast to 30% of patients in which clearance
marginsweredeemedinadequate.Whenlocalrecurrencedid
occur,thiswasassociatedwithaworseoutcomebutthetrend
did not reach statistical signiﬁcance. Other studies report
that the failure to achieve local control of the tumour bears a
major association with treatment failure and poor outcome
[26, 27].
Any patient with an MPNST in association with NF1
should be carefully staged prior to treatment and should be
managed by a multidisciplinary team familiar with both soft
tissue sarcomas and NF1. In those patients who were treated
withcurativeintentandhadamarginalresection,recurrence
rates remained low 3/32. Therefore, we recommend that
postoperative surveillance should remain in accordance with
current NICE sarcoma guidelines [28] and NF1 conference
statement [10].
We conclude that as NF1 is an independent indicator of
poor prognosis in MPNSTs, we recommend that this must
be taken into account during the tumour staging. It may be
necessary to have separate staging systems for sporadic and
NF1-associated tumours to reﬂect this. As the survival rate
in the NF group was dependant on tumour volume, routine
screening of these patients with FDG PET and or MRI may
be warranted, thereby staging and controlling them at the
earliest possible opportunity.
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